Zobrazeno 1 - 10
of 896
pro vyhledávání: '"Zwiebel JA"'
Autor:
Wisinski KB; Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI., Flamand Y; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wilson MA; Department of Oncology, Division of Hematology/Medical Oncology, St Luke's University Health Network, Easton, PA., Luke JJ; Division of Hematology/Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA., Tawbi HA; MD Anderson Cancer Center, Houston, TX., Hong F; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Chen H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Li S; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; Department of Pathology, City of Hope, Duarte, CA., Behrens RJ; Iowa-Wide Oncology Research Association NCORP, Des Moines, IA., Pennington KP; Fred Hutchinson Cancer Research Center, Seattle, WA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2023 Apr; Vol. 7, pp. e2200421.
Autor:
Bedard PL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Li S; E-A Biostatistical Center, Boston, MA., Wisinski KB; University of Wisconsin Carbone Cancer Center, Madison, WI., Yang ES; University of Alabama-Birmingham, Birmingham, AL., Limaye SA; Kokilaben Dhirubhai Ambani Hospital, Mumbai, India (Current)., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Moscow JA; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Cancer Cancer Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2200165.
Autor:
Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jegede OA; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Grilley-Olson JE; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Lauring JD; Johns Hopkins School of Medicine, Baltimore, MD., Mitchell EP; Thomas Jefferson University, Philadelphia, PA., Zwiebel JA; National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; National Cancer Institute, Bethesda, MD., Rubinstein LV; National Cancer Institute, Bethesda, MD., Patton D; National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Kono SA; Colorado Permanente Medical Group, Lone Tree, CO., Ford JM; Stanford University, Stanford, CA., Garcia AA; Louisiana State University Health Science Center, New Orleans, LA., Sui XD; Providence Regional Cancer System, Lacey, WA., Siegel RD; Bon Secours St Francis Hospital, Greenville, SC., Slomovitz BM; University of Miami, Miami, FL., Conley BA; National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100424.
Autor:
Jhaveri KL; Department of Medicine, Memorial Sloan-Kettering Center, New York, USA. Electronic address: jhaverik@mskcc.org., Wang XV; Biostatistics, E-A Biostatistical Center, Boston, USA., Makker V; Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA., Luoh SW; Knight Cancer Institute, Oregon Health Science University, Portland, USA., Mitchell EP; Medical Oncology, Thomas Jefferson University, Philadelphia, USA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA., Sharon E; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA., Gray RJ; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA., Li S; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA., McShane LM; Biometric Research Branch, National Cancer Institute, Bethesda, USA., Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, USA., Patton D; Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda, USA., Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA., Hamilton SR; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA., Arteaga CL; Department of Internal Medicine, University of Texas Southwestern, Dallas, USA., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA., O'Dwyer PJ; University of Pennsylvania, Philadelphia, USA., Chen AP; CTEP, National Cancer Institute, Bethesda, USA., Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, USA.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Aug; Vol. 32 (8), pp. 1068. Date of Electronic Publication: 2021 Jun 05.
Autor:
Cleary JM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. jcleary@partners.org., Wang V; Dana-Farber Cancer Institute, Boston, Massachusetts., Heist RS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Kopetz ES; University of Texas MD Anderson Cancer Center, Houston, Texas., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kapner KS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Li S; Dana-Farber Cancer Institute, Boston, Massachusetts., Gray RJ; Dana-Farber Cancer Institute, Boston, Massachusetts., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland., Meric-Bernstam F; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Dillmon MS; Harbin Clinic Medical Oncology and Clinical Research. Rome, Georgia., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hamilton SR; University of Texas MD Anderson Cancer Center, Houston, Texas., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Aguirre AJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Arteaga CL; UT Southwestern Medical Center, Dallas, Texas., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 2996-3004. Date of Electronic Publication: 2021 Feb 26.
Autor:
Huang, Danxue1 (AUTHOR) huangdanxue@163.com, Li, Su1 (AUTHOR), Bai, Yang1 (AUTHOR), Wang, Yan1 (AUTHOR)
Publikováno v:
BMC Cancer. 10/22/2024, Vol. 24 Issue 1, p1-9. 9p.
Autor:
Wang, Junke1,2,3 (AUTHOR), Yang, Jie4,5 (AUTHOR), Narang, Amol2,3,6 (AUTHOR), He, Jin2,3,6,7 (AUTHOR), Wolfgang, Christopher8 (AUTHOR), Li, Keyu2,3,4 (AUTHOR) keyu_li@scu.edu.cn, Zheng, Lei2,3,6,7,9 (AUTHOR) lzheng6@jhmi.edu
Publikováno v:
Journal of Hematology & Oncology. 10/11/2024, Vol. 17 Issue 1, p1-59. 59p.
Autor:
Ha, Hyerim1 (AUTHOR), Lee, Hee Yeon2 (AUTHOR), Kim, Jee Hyun3 (AUTHOR), Kim, Do Yeun4 (AUTHOR), An, Ho Jung5 (AUTHOR), Bae, SeungJin6 (AUTHOR), Park, Hye-sung7 (AUTHOR) hye_sung_park@naver.com, Kang, Jin Hyoung7 (AUTHOR) oncologykang@naver.com
Publikováno v:
Cancer Research & Treatment. Oct2024, Vol. 56 Issue 4, p991-1013. 23p.
Autor:
Liu, Zhe1,2 (AUTHOR), Petinrin, Olutomilayo Olayemi2 (AUTHOR), Chen, Nanjun2 (AUTHOR), Toseef, Muhammad2 (AUTHOR), Liu, Fang3 (AUTHOR), Zhu, Zhongxu4 (AUTHOR) zhuzhongxu@him.cas.cn, Qi, Furong1 (AUTHOR) qifurong2012@gmail.com, Wong, Ka-Chun2,5 (AUTHOR) kc.w@cityu.edu.hk
Publikováno v:
BMC Infectious Diseases. 10/3/2024, Vol. 24 Issue 1, p1-28. 28p.
Autor:
Tufail, Muhammad1 (AUTHOR), Jiang, Can-Hua1,2,3,4 (AUTHOR), Li, Ning1,2,3,4 (AUTHOR) liningoms@csu.edu.cn
Publikováno v:
Molecular Cancer. 9/18/2024, Vol. 23 Issue 1, p1-40. 40p.